Crossmark

Rhynchophylline alleviates early atherosclerosis by attenuating oxidized low-density lipoprotein-induced foam cell formation and endothelial dysfunction

Crossref DOI link: https://doi.org/10.1007/s11010-025-05418-5

Published Online: 2025-10-24

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Prasannan, Jeeva

Sobha, Archana

Jaleel, Abdul

Mohanakumari, Vinod Vikraman Thambi

Ramachandran, Surya
License Information

Text and Data Mining valid from 2025-10-24

Version of Record valid from 2025-10-24
More Information

Article History

Received: 9 August 2025

Accepted: 12 October 2025

First Online: 24 October 2025

Declarations

:

: The authors have declared that they have no conflicts of interest.

: The study was approved by the Institutional Animal Ethics Committee (IAEC), Rajiv Gandhi Centre for Biotechnology (protocol no. IAEC/870/SURYA/2022, IAEC/870/JALEEL/2025).

Document is current

Any future updates will be listed below